BioArctic AB's (publ) partner Eisai today announced that the European Commission has asked the Committee for Medicinal Products for Human Use (CHMP) to consider two additional questions. These ...

Paris: Following the adoption of a positive opinion by the European Medicines Agency's (EMA) Committee for Medicinal Products ...

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

Bristol Myers on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Breyanzi for the treatment of adults with relapsed or refractory ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...

AstraZeneca PLC (LSE/STO/NASDAQ:LON:AZN), a pharmaceutical giant with a market capitalization of $215.44 billion and impressive gross profit margins of 82.61%, has received a recommendation for ...

Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its 21-valent pneumococcal conjugate ...

AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...

The acquisition of RayzeBio added its proprietary radiopharmaceutical ... Earlier, the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency recently gave ...

SHELTON, CT / ACCESS Newswire / January 27, 2025 / NanoViricides, Inc. (NYSE American: NNVC) (the 'Company') today announced that it has engaged a Clinical Research Organization (CRO) to conduct a ...

Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

In the US, the non-proprietary name for Sarclisa is isatuximab-irfc ... On November 14, 2024, the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) adopted a ...